AI in Drug Discovery: Mapping the Value Chain

Where is AI actually changing how drugs are discovered and developed? This interactive report maps 158 public and 195 private companies across the drug development value chain, from discovery services and lab tools to clinical developers and large pharma, and classifies each by AI focus and modality. Alongside the map, 705 sourced statements from earnings calls, SEC filings and company releases show what management teams say AI has, and has not, changed.